Scientific Resources
We work closely with academic institutions and research teams worldwide to assist in new discoveries and innovation. To date, we have enabled more than 130 publications across a wide variety of scientific fields
Publications
Below are some selected scientific publications we have enabled.
For a list of all 130+ publications press here.
Virus-like particle display of HER2 induces potent anti-cancer responses
Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20–30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.
OncoImmunology, Volume 7, Issue 30, 2018.
Arianna Palladini, Susan Thrane, Christoph M. Janitzek, Jessica Pihl, Stine B. Clemmensen, Willem Adriaan de Jongh, Thomas M. Clausen, Giordano Nicoletti, Lorena Landuzzi, Manuel L. Penichet, Tania Balboni, Marianna L. Ianzano, Veronica Giusti, Thor G. Theander, Morten A. Nielsen, Ali Salanti, Pier-Luigi Lollini, Patrizia Nanni & Adam F. Sander
Label-free in-flow detection of receptor recognition motifs on the biomolecular corona of nanoparticles
Proteins and other biomolecules in human biological fluids interact with the surfaces of nanoparticles. These interactions generate a coating (corona) around the nanoparticles which is the nanoparticles interface in the human body. Attana´s technology was used to characterized corona coated nanoparticles interactions with different biomolecules. The obtained information is a valuable tool to optimize nanoparticles for therapeutic applications and to improve the predictability of in vivo performance of the nanoparticles. During the EU-project several different assays have been developed based on Attana’s technology and some of the results have now been published in the journal Nanoscale. In the paper, accessible functional epitopes of transferrin-coated nanoparticles are quantified and their number is correlated to differences in nanoparticle size and functionalization. The label free in flow target recognition pushes the assays into a more in vivo-like scenario than previous technologies. The assays are applicable to a wide array of nanoparticles and consequently hold the potential to become a standard technique for the classification of nanoparticles based on their biological external functionality.
Nanoscale, vol. 10, 2018, p. 5474-5481.
M. Gianneli, E. Polo, H. Lopez, V. Castagnola, T. Aastrup & K.A. Dawson.
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
In a study made by Ali Salanti et al. regarding binding between human cancer cells and glycosaminoglycan binding malaria protein (VAR2CSA). The study utilises Attana QCM technology to perform binding studies using both cell based and biochemical approaches.
Cancer Cell, Volume 28, Issue 4, p. 500–514, 2015.
Ali Salanti, Thomas M. Clausen, Mette Ø. Agerbæk, Nader Al Nakouzi, Madeleine Dahlbäck, Htoo Z. Oo, Sherry Lee, Tobias Gustavsson, Jamie R. Rich, Bradley J. Hedberg, Yang Mao, Line Barington, Marina A. Pereira, Janine LoBello, Makoto Endo, Ladan Fazli, Jo Soden, Chris K. Wang, Adam F. Sander, Robert Dagil, Susan Thrane, Peter J. Holst, Le Meng, Francesco Favero, Glen J. Weiss, Morten A. Nielsen, Jim Freeth, Torsten O. Nielsen, Joseph Zaia, Nhan L. Tran, Jeff Trent, John S. Babcook, Thor G. Theander, Poul H. Sorensen and Mads Daugaard
Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting
The paper describes use of Attana QCM label free methodology to study molecular binding kinetics in situ on FFPE tissues. FFPE tissue sections of human placenta tissues and prostate cancer were immobilised on COP-1 surfaces using ploy-L-lysine solution. Interaction between vAR2 protein and its receptor has been analysed using Attana Cell 200 system. Affinity value in the nanomolor range was detected for the interaction between rVAR2 and its receptor and no detectable binding was observed with the haelthy tissues.
Sensing and Bio-Sensing Research, Volume 9, p. 23-30, 2016.
Thomas Mandel Clausen, Marina Ayres Pereira, Htoo Zarni Oo, Mafalda Resende, Tobias Gustavson, Yang Mao, Nobuo Sugiura, Janet Liew, Ladan Fazli, Thor G Theander, Mads Daugaard and Ali Salanti
Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors
This study explores the effect of cell surface glycans on cancer therapy.
Scientific Reports 7, Article: 43006, 2017.
Diluka Peiris, Alexander F. Spector, Hannah Lomax-Browne, Tayebeh Azimi, Bala Ramesh, Marilena Loizidou, Hazel Welch and Miriam V. Dwek
Combined Bacteria Microarray and Quartz Crystal Microbalance Approach for Exploring Glycosignatures of Nontypeable Haemophilus influenzae and Recognition by Host Lectins
The paper describes the use of the Attana Cell 200 instrument to characterize the glycosignature of bacteria (haemophilus influeanze). The bacteria have been immobilized using a ConA-LNB surface. Different lectins injected and the binding kinetic analyze. Comparison of the frequency shift obtained using different strains confirm the result obtained in micro-array.
Analytic Chemistry, Volume 88, Issue 11, p. 5950–5957, 2016.
Ioanna Kalograiaki, Begoñ a Euba,Davide Proverbio, María A. Campanero-Rhodes, Teodor Aastrup, Junkal Garmendia and Dolores Solís
Projects & collaborations
Active projects
NanoCarb: Development of glycosylated nanoparticles with enhanced therapeutic actions
NanoCarb: Development of glycosylated nanoparticles with enhanced therapeutic actions
Participants - Royal College of Surgeons in Ireland, University of Warwick, Università degli Studi di Milano, CIC biomaGUNE, Vlaamse Instelling voor Technologisch Onderzoek, Ludger Ltd, Midatech Pharma, Mario Negri Institute for Pharmacological Research.
The overarching aim of the NanoCarb ETN project is to develop glycosylated nanoparticles with enhanced therapeutic actions for healthcare applications. 15 Early Stage Researchers (ESRs) recruited for the NanoCarb project will work on their individual ESR projects designed to provide appropriate research goals for PhD students. Each ESR will be exposed to a well-balanced and optimal experience in academia, industry and research centre in order to increase their research experience and scientific maturity.
Concluded projects
Development of CD34/CD3 bispecific antibodies for treatment of leukemia and preconditioning before allogeneic hematopoietic stem cell transplantation
Participants - Karolinska Universitetsjukhuset, Kungliga Tekniska Högskolan, Attana AB.
The aim of the project Specific aims of the project to design a range of bispecific antibodies towards CD34 (stem cells and leukemic cells) and CD3 (T cells) and to identify and select lead candidates by evaluating binding properties towards cell-surface bound antigen by Attanas' cell based assays.
CellSenseGels: Development of sensitive and robust cell-based biosensor assay platforms using peptide gel matrices
Participants - University Stuttgart, Biogelx Ltd, Attana AB.
The project will develop a robust sensitive platform for measurements of molecular kinetics, using peptide hydrogel technology as a 3D matrix. The gels will offer a tissue-mimicking environment, ensuring increased biological relevance and greater data quality. Furthermore, this sensor will improve the range and data quality of biosensor assays through increased signal strength and reduced background noise. Product will be cell-type optimized kits incorporating customised gel-matrices.
NanoClassifier: QCM for rapid label-free Bionano interface evaluation and screening of effectiveness of nano-targeting strategies for therapeutics.
Participants - University College Dublin, Attana AB.
Nanomedicine and Nanosafety rely on the same fundamental interactions between the nanoparticle interface and the biological milieu surrounding it, and it is this “corona” of proteins and other biomolecules that form at the bionanointerface that determines the fate and behaviour of nanomaterials. Understanding, classifying and predicting nanoparticle coronas from their physicochemical properties offers a novel approach to screening for toxicity at early stages of product development and for regulatory purposes.
Quality Control and Purification of New Biological Pharmaceuticals
Participants: Astra Zeneca AB, Attana AB, Akzo Nobel Pulp and Performance Chemicals AB and Karlstad University and three more partners.
Thursday November 30th 2017 the project BIO-QC "Quality Control and Purification of New Biological Pharmaceuticals" was initiated. Biological pharmaceuticals are proteins or similar molecules, which mimics molecules in the body and are injected in the body to stimulate the immune system. To provide criteria’s for quality control of biological pharmaceuticals.
The project has a budget of approximately €2 million and includes seven different parties, Attana AB, AstraZeneca, Akzo Nobel Pulp and Performance Chemicals AB and Ridgeview Instruments AB and Karlstad University, Linné University and Örebro University.